Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults.
Epidemiology
Viral infection
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
01
2021
accepted:
17
06
2021
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
In spring 2020, at the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Europe, we set up an assay system for large-scale testing of virus-specific and neutralising antibodies including their longevity. We analysed the sera of 1655 adult employees for SARS-CoV-2-specific antibodies using the S1 subunit of the spike protein of SARS-CoV-2. Sera containing S1-reactive antibodies were further evaluated for receptor-binding domain (RBD)- and nucleocapsid protein (NCP)-specific antibodies in relation to the neutralisation test (NT) results at three time points over six months. We detect immunoglobulin G (IgG) and/or IgA antibodies reactive to the S1 protein in 10.15% ( RBD-specific antibodies are most reliably detected post-infection, independent of the number/severity of symptoms, and correlate with neutralising antibodies at least for six months. They thus qualify best for large-scale seroepidemiological evaluation of both antibody reactivity and virus neutralisation.
Sections du résumé
Background
UNASSIGNED
In spring 2020, at the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Europe, we set up an assay system for large-scale testing of virus-specific and neutralising antibodies including their longevity.
Methods
UNASSIGNED
We analysed the sera of 1655 adult employees for SARS-CoV-2-specific antibodies using the S1 subunit of the spike protein of SARS-CoV-2. Sera containing S1-reactive antibodies were further evaluated for receptor-binding domain (RBD)- and nucleocapsid protein (NCP)-specific antibodies in relation to the neutralisation test (NT) results at three time points over six months.
Results
UNASSIGNED
We detect immunoglobulin G (IgG) and/or IgA antibodies reactive to the S1 protein in 10.15% (
Conclusions
UNASSIGNED
RBD-specific antibodies are most reliably detected post-infection, independent of the number/severity of symptoms, and correlate with neutralising antibodies at least for six months. They thus qualify best for large-scale seroepidemiological evaluation of both antibody reactivity and virus neutralisation.
Identifiants
pubmed: 35602189
doi: 10.1038/s43856-021-00012-4
pii: 12
pmc: PMC9037317
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Competing interestsThe authors A.W. A.G., J.R., J.J., I.Z., U.S., E.H., M.K., H.S. and U.W. declare no competing interest within the scope of this manuscript. M.R.F. and T.R.K. are employees of Baxter AG, now part of the Takeda group of companies, Vienna, Austria and have Takeda stock interest.
Références
Am J Clin Pathol. 2020 Oct 13;154(5):610-619
pubmed: 32808976
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Brain Behav. 2020 Nov;10(11):e01839
pubmed: 32935915
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Travel Med Infect Dis. 2020 Nov - Dec;38:101909
pubmed: 33152512
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
JAMA. 2020 Nov 3;324(17):1781-1782
pubmed: 32940635
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Emerg Microbes Infect. 2020 Dec;9(1):2091-2093
pubmed: 32930052
Am J Clin Pathol. 2020 Aug 5;154(3):293-304
pubmed: 32583852
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
Am J Clin Pathol. 2020 Jun 8;154(1):1-3
pubmed: 32412044
J Infect Dis. 2020 Nov 13;222(12):1960-1964
pubmed: 32941626
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Sci Immunol. 2020 May 19;5(47):
pubmed: 32430309
Euro Surveill. 2020 May;25(18):
pubmed: 32400364
J Infect Dis. 2020 Oct 1;222(9):1452-1461
pubmed: 32766833
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822
pubmed: 32249185
JAMA. 2020 May 19;323(19):1908-1909
pubmed: 32275299
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
J Infect Dis. 2020 Jul 6;222(3):362-366
pubmed: 32473021
Nat Med. 2020 Aug;26(8):1171-1172
pubmed: 32719488
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034